PAAJX
Price
$14.41
Change
+$0.21 (+1.48%)
Updated
Sep 19 closing price
PAAQX
Price
$14.41
Change
+$0.21 (+1.48%)
Updated
Sep 19 closing price
Ad is loading...

PAAJX vs PAAQX

Header iconPAAJX vs PAAQX Comparison
Open Charts PAAJX vs PAAQXBanner chart's image
Invesco Active Allocation R5
Price$14.41
Change+$0.21 (+1.48%)
VolumeN/A
CapitalizationN/A
Invesco Active Allocation R6
Price$14.41
Change+$0.21 (+1.48%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
PAAJX vs PAAQX Comparison Chart
Loading...
VS
PAAJX vs. PAAQX commentary
Sep 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAAJX is a Sell and PAAQX is a Sell.

FUNDAMENTALS
Fundamentals
PAAJX (1.94B) and PAAQX (1.94B) have equal amount of cash in the bank . PAAQX (1.92) and PAAJX (1.92) have matching dividends . PAAJX was incepted earlier than PAAQX: PAAJX (5 years) vs PAAQX (5 years). PAAJX (21.00) and PAAQX (21.00) have comparable annual turnover. PAAJX (1000000) and PAAQX (1000000) have matching initial minimum investment requirements. PAAQX (14.74) and PAAJX (14.63) have marching annual gain over last year. PAAQX (5.03) and PAAJX (4.91) have equivalent 5 years return.
PAAJXPAAQXPAAJX / PAAQX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years5 years-
Gain YTD8.7298.81299%
Front LoadN/AN/A-
Min. Initial Investment10000001000000100%
Min. Initial Investment IRAN/AN/A-
Net Assets1.94B1.94B100%
Annual Yield % from dividends1.921.92100%
Returns for 1 year14.6314.7499%
Returns for 3 years-8.47-8.39101%
Returns for 5 years4.915.0397%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TCRT3.090.65
+26.64%
Alaunos Therapeutics Inc.
HTZ3.710.05
+1.37%
Hertz Global Holdings
TREX68.000.14
+0.21%
Trex Company
ARQQ0.30N/A
-0.07%
Arqit Quantum
CRBP49.45-1.45
-2.85%
Corbus Pharmaceuticals Holdings